BWI: US FDA Extends License of the GVK BIO Biomarker Database

Press release from Business Wire India
Source: GVK Biosciences Private Limited
Monday, February 04, 2013 12:00 PM IST (06:30 AM GMT)
Editors: General: Consumer interest, People; Business: Advertising, PR & marketing, Business services, Chemicals, Healthcare, biotechnology & pharmaceutical; Technology; Healthcare
--------------------------------------------------
US FDA Extends License of the GVK BIO Biomarker Database


Hyderabad, Andhra Pradesh, India, Monday, February 04, 2013 -- (Business Wire India) -- GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the USFDA in its Biomarker Qualification Process.

The GOBIOM database is a comprehensive compilation of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 20,000 biomarkers comprising of biochemical, genomic, imaging, metabolite, cellular and physiological markers, along with multiple data points comprising of experimental, analytical, clinical and statistical data with their qualifications under different medical interventions.

Sreeni Devidas, Vice President, Sales & Marketing, Informatics said, "The collaboration with the USFDA has helped GVK BIO in developing the safety biomarker content in GOBIOM. The interconnectivity between organ toxicities to the drug, dose and population was developed with equal emphasis on its preclinical qualification. Biomarker analysis tools were integrated into the database in a manner that has facilitated the user to make a comparative analysis between the biomarkers of their interest. We look forward to continue working and collaborating with the FDA with a view to enhancing the utility of the product further."

About GVK BIO

GVK Biosciences (GVK BIO) is Asia's leading discovery, research and development organization providing a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO's diverse portfolio and global clientele comprising more than 200 customers includes some of the global leading organizations in the fields of pharmaceuticals, biotechnology, agro, life-sciences as well as prestigious academic institutions. Please visit us at www.gvkbio.com to know more.


CONTACT DETAILS
Sreeni Devidas, Vice President - Business Development, GVK Biosciences Private Limited, (443)-838-6260, sreeni.devidas@gvkbio.com
Sushant Datta, DGM - Corporate Brand & Communications, GVK Biosciences Private Limited, +91 (40) 66929999, sushant.datta@gvkbio.com

KEYWORDS
CONSUMER, PEOPLE, MARKETING, BUSINESS SERVICES, CHEMICALS, HEALTHCARE, TECHNOLOGY, HEALTHCARE

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com